ExonHit Shareholder Meeting on RedPath Buy Likely Delayed

ExonHit said that it anticipates a lack of quorum to vote on the acquisition, which last week hit a snag on the news that Medicare may drop RedPath's pancreatic cancer test.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories